C4 Therapeutics (CCCC) Common Equity (2019 - 2026)

C4 Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $234.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 20.04% year-over-year to $234.2 million; the TTM figure through Mar 2026 stood at $234.2 million (up 20.04% YoY), while the FY2025 annual figure was $256.6 million, up 18.8% from the prior year.
• Common Equity was $234.2 million for Q1 2026 at C4 Therapeutics, down from $256.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $364.5 million in Q1 2022 to a low of $154.4 million in Q3 2025.
• Historically, Common Equity has averaged $250.2 million across 5 years, with a median of $246.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 38.23% in 2022, then plunged 36.37% in 2025.
• A 5-year view of Common Equity shows it stood at $289.2 million in 2022, then dropped by 14.91% to $246.1 million in 2023, then dropped by 12.24% to $216.0 million in 2024, then climbed by 18.8% to $256.6 million in 2025, then dropped by 8.71% to $234.2 million in 2026.
• The last three Common Equity figures came in at $234.2 million (Q1 2026), $256.6 million (Q4 2025), and $154.4 million (Q3 2025), per Business Quant data.